2cureX Management

Management criteria checks 1/4

2cureX's CEO is Kenneth Johansen, appointed in Feb 2021, has a tenure of 3.17 years. directly owns 0.023% of the company’s shares, worth €152.45. The average tenure of the management team and the board of directors is 3.2 years and 2.6 years respectively.

Key information

Kenneth Johansen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.2yrs
CEO ownership	0.02%
Management average tenure	3.2yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO

Kenneth Johansen (47 yo)

3.2yrs

Tenure

Mr. Kenneth Graabek Johansen serves as Chief Financial Officer at 2cureX AB (publ) since February 1, 2021 and serves as it's Acting Chief Executive Officer since December 29, 2023. He serves as COO and Co-...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ole Thastrup	Co-Founder & Vice Chairman	18.3yrs	kr150.00k	23.8% SEK 159.7k
Kenneth Johansen	Acting CEO & CFO	3.2yrs	no data	0.023% SEK 152.4
Grith Hagel	Co-Founder	no data	no data	3.87% SEK 26.0k
Jacob Thastrup	Chief Technology Officer	less than a year	no data	0.062% SEK 416.2
Manuel Fernandez	Director Quality & Regulatory Affairs	no data	no data	no data

3.2yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 2QE's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ole Thastrup	Co-Founder & Vice Chairman	18.3yrs	kr150.00k	23.8% SEK 159.7k
Grith Hagel	Co-Founder	less than a year	no data	3.87% SEK 26.0k
John Marshall	Member of Clinical Advisory Board	2.8yrs	no data	no data
Jesus Garcia-Foncillas	Member of Clinical Advisory Board	2.8yrs	no data	no data
Andrew Beggs	Member of Clinical Advisory Board	2.4yrs	no data	no data
Tonni Bulow-Nielsen	Chairman of the Board	less than a year	no data	no data

2.6yrs

Average Tenure

Experienced Board: 2QE's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

2cureX Management

Management criteria checks 1/4

Key information

Recent management updates

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

2cureX AB (publ), Annual General Meeting, May 23, 2024

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

High number of new and inexperienced directors

Recent updates

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

New 90-day high: €2.19

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: €1.83

2cureX Announces Management Changes

New 90-day high: €1.66

2cureX AB (publ), Annual General Meeting, May 27, 2021

New 90-day low: €1.50

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: €1.62

2cureX launches world's first CE-marked microtumor test service

New 90-day high - €2.15

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure